BUND FINANCE › Stocks › RPRX
Royalty Pharma plc (RPRX)
NASDAQ · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +11.18% above its 50-day average.
- It is +25.10% above its 200-day average (long-term uptrend).
- It sits at 95% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$2.3B | US$2.2B | US$2.4B | US$2.3B | US$2.4B |
| Net income | US$619.7M | US$42.8M | US$1.1B | US$859.0M | US$770.9M |
| EPS (diluted) | 1.49 | 0.10 | 2.53 | 1.91 | 1.78 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| Net margin | 27.1% | 1.9% | 48.2% | 38.0% | 32.4% |
| Free cash flow | US$2.0B | US$2.1B | US$3.0B | US$2.8B | US$2.5B |
| Total debt | US$7.1B | US$7.1B | US$6.1B | US$7.6B | US$9.0B |
| Cash | US$1.5B | US$1.7B | US$477.0M | US$929.0M | US$618.7M |
Compound annual growth: revenue 1.0% · net income 5.6% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 51.6x | 92.0x | 27.1x |
| EV / EBITDA | 25.0x | 21.1x | 16.5x |
| Operating margin | 59.8% | — | 3.6% |
| Net margin | 25.7% | — | -0.0% |
| Debt / equity | 1.41 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice